• OASMIA RESOLVES ON A FULLY SECURED RIGHTS ISSUE OF APPROXIMATELY SEK 151 MILLION

    The company will hold an online presentation today at 14:00 CET.
    The presentation will be given by CEO Francois Martelet and CFO Fredrik Järrsten, in English.

Read our Management Stories

XR-17 is Oasmia’s proprietary delivery platform

CEO corner

Get to learn more about Francois Martelet, our CEO

Oasmia Pharmaceutical published its Q3 2021 report on November 18, 2021, at 08.00 am CET.

The company will hold a conference call and an online presentation on the same day at 10.00 am CET. The call will be hosted by CEO Francois Martelet and CFO Fredrik Järrsten. The presentation will be in English.

The Share

Oasmia acquires global development and commercialization rights for Cantrixil, a clinical stage, ovarian cancer program

Annual Report 2020